chr3-48467513-GCTGCTGGCCCCACTGGGT-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM4PP5_Very_Strong
The NM_033629.6(TREX1):c.868_885del(p.Pro290_Ala295del) variant causes a inframe deletion change. The variant allele was found at a frequency of 0.000088 in 1,613,926 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000059 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000091 ( 0 hom. )
Consequence
TREX1
NM_033629.6 inframe_deletion
NM_033629.6 inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 3.94
Genes affected
TREX1 (HGNC:12269): (three prime repair exonuclease 1) This gene encodes a nuclear protein with 3' exonuclease activity. The encoded protein may play a role in DNA repair and serve as a proofreading function for DNA polymerase. Mutations in this gene result in Aicardi-Goutieres syndrome, chilblain lupus, Cree encephalitis, and other diseases of the immune system. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2012]
ATRIP (HGNC:33499): (ATR interacting protein) This gene encodes an essential component of the DNA damage checkpoint. The encoded protein binds to single-stranded DNA coated with replication protein A. The protein also interacts with the ataxia telangiectasia and Rad3 related protein kinase, resulting in its accumulation at intranuclear foci induced by DNA damage. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM4
Nonframeshift variant in NON repetitive region in NM_033629.6.
PP5
Variant 3-48467513-GCTGCTGGCCCCACTGGGT-G is Pathogenic according to our data. Variant chr3-48467513-GCTGCTGGCCCCACTGGGT-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 126393.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-48467513-GCTGCTGGCCCCACTGGGT-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TREX1 | NM_033629.6 | c.868_885del | p.Pro290_Ala295del | inframe_deletion | 2/2 | ENST00000625293.3 | NP_338599.1 | |
ATRIP | NM_130384.3 | c.*1969_*1986del | 3_prime_UTR_variant | 13/13 | ENST00000320211.10 | NP_569055.1 | ||
ATRIP-TREX1 | NR_153405.1 | n.4177_4194del | non_coding_transcript_exon_variant | 15/15 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TREX1 | ENST00000625293.3 | c.868_885del | p.Pro290_Ala295del | inframe_deletion | 2/2 | NM_033629.6 | ENSP00000486676 | P1 | ||
ATRIP | ENST00000320211.10 | c.*1969_*1986del | 3_prime_UTR_variant | 13/13 | 1 | NM_130384.3 | ENSP00000323099 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000591 AC: 9AN: 152214Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
9
AN:
152214
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000637 AC: 16AN: 251074Hom.: 0 AF XY: 0.0000516 AC XY: 7AN XY: 135790
GnomAD3 exomes
AF:
AC:
16
AN:
251074
Hom.:
AF XY:
AC XY:
7
AN XY:
135790
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000910 AC: 133AN: 1461712Hom.: 0 AF XY: 0.0000853 AC XY: 62AN XY: 727174
GnomAD4 exome
AF:
AC:
133
AN:
1461712
Hom.:
AF XY:
AC XY:
62
AN XY:
727174
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152214Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74366
GnomAD4 genome
AF:
AC:
9
AN:
152214
Hom.:
Cov.:
33
AF XY:
AC XY:
2
AN XY:
74366
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:13Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Aicardi-Goutieres syndrome 1 Pathogenic:4Other:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Suma Genomics, Suma Genomics | - | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.006%). Inframe deletion located in a nonrepeat region: predicted to change the length of the protein and disrupt normal protein function. The variant has been reported at least twice as pathogenic without evidence for the classification (ClinVar ID: VCV000126393 / PMID: 17846997). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 27, 2023 | Variant summary: TREX1 c.868_885del18 (p.Pro290_Ala295del), also referred to as c.859_876del18 (p.Leu287_Gly292del), results in an in-frame deletion that is predicted to remove six amino acids from the encoded protein. The variant allele was found at a frequency of 6.4e-05 in 251074 control chromosomes (gnomAD). c.868_885del18 has been reported in the literature in multiple individuals affected with Aicardi Goutieres Syndrome 1, including homozygous patients from at least three different families (e.g. Rice_2007, Ramantani_2010, Abe_2014, Crow_2015). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 24300241, 25604658, 20131292, 17846997). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all laboratories classified the variant as either pathogenic (n=2) or likely pathogenic (n=3). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden | Nov 03, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2022 | TREX1: PM3:Strong, PM2, PM4 - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 07, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 14, 2023 | In-frame deletion of six amino acids in a non-repeat region; In silico analysis supports a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20301648, 17846997, 25582466, 20131292, 28750028, 31719132, 29387804, 31130681, 24300241, 27943079, 35551623, 34426522, 33683010, 37081257) - |
Aicardi Goutieres syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Pediatrics, Sichuan Provincial Hospital For Women And Children | - | The proband, male, 3 months old, was found to have widened lateral ventricles during the fetal period, had feeding difficulties after birth, did not gain weight, and was found to have microcephaly and nystagmus by physical examination. MRI revealed calcification in the skull, thrombocytopenia in blood routine, and elevated aminotransferase in liver function. During the follow-up observation period of more than 1 year, the patient developed recurrent chilblains and pneumonia and global development delay. - |
TREX1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 19, 2024 | The TREX1 c.868_885del18 variant is predicted to result in an in-frame deletion (p.Pro290_Ala295del). This variant has been reported as causative in several patients with autosomal recessive Aicardi-Goutières syndrome (described as p.Pro290_Ala295del, Abe et al. 2014. PubMed ID: 24300241; Rice et al. 2007. PubMed ID: 17846997; Tise et al. 2021. PubMed ID: 33683010). This variant is reported in 0.026% of alleles in individuals of South Asian descent in gnomAD. This variant is interpreted as pathogenic. - |
Systemic lupus erythematosus;C0024145:Chilblain lupus 1;C0796126:Aicardi-Goutieres syndrome 1;C1860518:Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 29, 2022 | - - |
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Breakthrough Genomics, Breakthrough Genomics | Oct 23, 2019 | This variant (represented as c.868_885del/c.859_876del in articles) was previously reported as pathogenic in homozygous state or compound heterozygous state in patients affected with AGS [PMID: 17846997, 20131292, 24300241, 28750028]. Heterozygous TREX1 mutations were described in a cutaneous form of SLE-called FCL [PMID:17440703] and in patients with an adult-onset RVCL [PMID: 16960810]. In addition, heterozygous TREX1 mutations were found in individuals with SLE [PMID:17660818]. - |
Chilblain lupus 1;C0796126:Aicardi-Goutieres syndrome 1;C1860518:Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 22, 2023 | This variant, c.868_885del, results in the deletion of 6 amino acid(s) of the TREX1 protein (p.Pro290_Ala295del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs776342560, gnomAD 0.03%). This variant has been observed in individual(s) with Aicardi Goutieres syndrome (PMID: 20131292, 24300241, 25582466, 28750028). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is also known as c.859_876del18; p.Leu287_Gly292del. ClinVar contains an entry for this variant (Variation ID: 126393). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at